November 28, 2017

Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update

TORONTO, CANADA — (November 28, 2017) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28th for the fiscal quarter ended September 30, 2017. The Corporation’s unaudited fiscal Q2 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. Dan Legault, Antibe’s CEO, commented, “Our … Continued

more
October 26, 2017

Antibe Therapeutics Announces Key US Distribution Partnership for its Subsidiary, Citagenix

Citagenix to be Regenerative Medicine Supplier for Darby Dental, a Leading Dental Distributor in the United States TORONTO, CANADA — (October 26, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc. (“Citagenix”), has been selected by Darby Dental Supply, LLC (“Darby Dental”) to … Continued

more
October 20, 2017

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

TORONTO, CANADA — (October 20, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the world’s largest pharma trade show and considered the leading international pharmaceutical business and networking event. The event will be held on … Continued

more
September 9, 2017

Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346

TORONTO, CANADA — (September 8, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), is pleased to announce that the first eight subjects have been enrolled and are on treatment in its key Phase 2B clinical trial, a double-blind, gastrointestinal (“GI”) safety study in 240 subjects with naproxen as a comparator. Naproxen … Continued

more
August 29, 2017

Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results

TORONTO, CANADA — (August 29, 2017) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Tuesday, August 29th for the fiscal quarter ended June 30, 2017. The Corporation’s unaudited fiscal Q1 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. Dan Legault, Antibe’s CEO, commented, “The … Continued

more
August 18, 2017

Antibe Therapeutics Announces Closing of Public Offering

Toronto, ON – (August 18, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the second and final closing of its previously announced marketed public offering of units (the “Units”) for additional gross proceeds of approximately $933,000 (the “Offering”).  In total, the Company has raised gross … Continued

more
July 28, 2017

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

TORONTO, CANADA — (July 28, 2017) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter and the year ended March 31, 2017. The Corporation’s audited 2017 financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer medicines … Continued

more
June 21, 2017

Antibe Therapeutics Announces Closing of Public Offering

Toronto, ON – (June 21, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the first closing of its previously announced marketed public offering of units (the “Units”) for gross proceeds of approximately $4,050,000 (the “Offering”). The Company issued 40,498,999 Units at a price of $0.10 per … Continued

more
June 15, 2017

Antibe Therapeutics Announces Filing of Final Short Form Prospectus

Toronto, ON – (June 15, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company“) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today that it has filed a final short form prospectus (the “Final Prospectus”) with securities regulators in Ontario, British Columbia and Alberta (the “Offering Jurisdictions”), relating to the Company’s marketed public offering … Continued

more
May 26, 2017

Antibe Therapeutics Announces Pricing of Offering

Toronto, ON – (May 26, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announces that it will file today an amended and restated preliminary short form prospectus (the “Amended and Restated Preliminary Prospectus”) with securities regulators in Ontario, British Columbia and Alberta, to amend and restate … Continued

more
May 24, 2017

Antibe Therapeutics Announces Proposed Offering of Units

Toronto, ON – (May 24, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today that it has filed a preliminary short form prospectus in connection with a proposed marketed offering of units of the Company (the “Units”) for minimum gross proceeds of $3,000,000 and maximum gross proceeds … Continued

more
May 12, 2017

Antibe Therapeutics Engages Topstone Research and Appoints Dr. Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346

TORONTO, CANADA — (May 12, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a diversified biotechnology company is providing an update on the clinical development program for ATB-346, its lead drug candidate targeting the global need for a safer remedy for chronic pain and inflammation. Antibe Engages Topstone Research Inc. Antibe’s … Continued

more
April 26, 2017

Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic

TORONTO, CANADA — (April 26, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that is has formally commenced Investigational New Drug (“IND”) enabling pre-clinical studies for its second pipeline drug, ATB-352, a non-addictive, potent analgesic for the treatment of severe pain. Dan Legault, Antibe’s CEO, commented, “There … Continued

more
March 31, 2017

Antibe Therapeutics Announces Grant of Stock Options

TORONTO, CANADA — (March 31, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company’s stock option plan. Each option has an exercise price of $0.20, being the … Continued

more
March 27, 2017

Antibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research

TORONTO, CANADA — (March 27, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce today that its founder and Chief Scientific Officer, Dr. John Wallace, is to receive the Horace W. Davenport Distinguished Lectureship in honour of his distinguished lifetime achievement in gastrointestinal and liver physiological research. This … Continued

more
March 7, 2017

Antibe Therapeutics Announces Results of Annual General Meeting

TORONTO, CANADA — (March 7, 2017) — Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the results of its annual general meeting held earlier today. All resolutions proposed to the shareholders were approved, including the election of management’s nominees (John Wallace, Daniel Legault, Walt Macnee, Roderick Flower, Samira Sakhia and Yung Wu) … Continued

more
March 1, 2017

Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results

TORONTO, CANADA — (March 1, 2017) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Wednesday, March 1st for the fiscal quarter ended December 31, 2016. The Corporation’s unaudited fiscal Q3 2017 condensed interim consolidated financial statements and MD&A are available on SEDAR. Dan Legault, Antibe’s CEO, commented, “We … Continued

more
February 24, 2017

Antibe Therapeutics Enters into Regional Licensing Deal

Secures strong regional partner for ATB-346 and further validates Antibe’s drug development program TORONTO, CANADA — (February 24, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce today that it has signed an exclusive licensing and distribution agreement with Laboratoires Acbel SA (“Acbel”) for ATB-346 in Greece, Romania, … Continued

more
February 20, 2017

Antibe Therapeutics Engages MKR Group for U.S. Investor Relations

TORONTO, CANADA — (February 20, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) today announced that it has retained MKR Group, Inc. (“MKR”) to create and execute a new proactive investor relations program addressing institutional investors and sell-side contacts in the U.S. financial markets. MKR will support the company’s North American … Continued

more
January 31, 2017

Antibe Therapeutics Announces the Launch of PentOS OI™ Max, its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery

TORONTO, CANADA — (January 31, 2017) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Max for the dental biologics market. PentOS OI™ Max is the newest member of the PentOS OI™ family of bone grafts for oral and maxillofacial surgery. PentOS OI™ Max … Continued

more
January 18, 2017

Antibe Therapeutics Announces Change of Auditor to Ernst & Young

TORONTO, CANADA — (January 18, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF)  announced today that its board of directors (the “Board”) has approved a change of the Company’s auditor. The Board has appointed Ernst & Young LLP (“EY”) as the new auditor and at the request of the Company, Zeifmans … Continued

more

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK